sevoflurane has been researched along with Lung Injury, Acute in 25 studies
Sevoflurane: A non-explosive inhalation anesthetic used in the induction and maintenance of general anesthesia. It does not cause respiratory irritation and may also prevent PLATELET AGGREGATION.
sevoflurane : An ether compound having fluoromethyl and 1,1,1,3,3,3-hexafluoroisopropyl as the two alkyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sevoflurane is considered as a lung-protective factor in acute lung injury (ALI), but the underlying molecular mechanism remains largely unknown." | 8.12 | Sevoflurane anesthesia ameliorates LPS-induced acute lung injury (ALI) by modulating a novel LncRNA LINC00839/miR-223/NLRP3 axis. ( Fu, Z; Wu, X; Zhang, Y; Zheng, F, 2022) |
| "Sevoflurane anesthesia is deemed as potential therapeutic drug for lipopolysaccharide (LPS)-induced acute lung injury (ALI), but the molecular mechanisms have not been fully delineated." | 8.12 | Activation of the AMPK-ULK1 pathway mediated protective autophagy by sevoflurane anesthesia restrains LPS-induced acute lung injury (ALI). ( Fu, Z; Wu, X; Zhang, Y; Zheng, F, 2022) |
| "Sevoflurane is identified as an effective candidate drug for acute lung injury (ALI) treatment, but its curing effects and detailed mechanisms have not been fully disclosed." | 8.12 | Sevoflurane reduces lipopolysaccharide-induced apoptosis and pulmonary fibrosis in the RAW264.7 cells and mice models to ameliorate acute lung injury by eliminating oxidative damages. ( Fu, Z; Wu, X; Zhang, J; Zhang, Y; Zheng, F, 2022) |
| "Sevoflurane (Sev) has protective effects in acute lung injury (ALI), but the relevant mechanisms are still not fully understood." | 8.02 | Sevoflurane inhibits ferroptosis: A new mechanism to explain its protective role against lipopolysaccharide-induced acute lung injury. ( Li, K; Liu, X; Ma, X; Mao, L; Si, J; Wang, L; Xing, Q, 2021) |
| "Evidence has shown that sevoflurane plays a protective role in acute lung injury (ALI) due to its anti-inflammatory and apoptotic-regulating activity." | 7.96 | Sevoflurane reduces inflammatory factor expression, increases viability and inhibits apoptosis of lung cells in acute lung injury by microRNA-34a-3p upregulation and STAT1 downregulation. ( Yuan, J; Zhang, Y, 2020) |
| " This investigation explored the protective effects of propofol and whether propofol potentiates the protective effects of sevoflurane against lipopolysaccharide (LPS)-induced acute lung injury." | 7.85 | Propofol Potentiates Sevoflurane-Induced Inhibition of Nuclear Factor--κB-Mediated Inflammatory Responses and Regulation of Mitogen-Activated Protein Kinases Pathways via Toll-like Receptor 4 Signaling in Lipopolysaccharide-Induced Acute Lung Injury in Mi ( Fang, H; Liu, W; Zhu, H, 2017) |
| "The aim of the present study was to explore the regulatory mechanism of heme oxygenase-1 (HO-1) expression induced by sevoflurane (Sevo) in lipopolysaccharide (LPS)‑induced acute lung injury (ALI)." | 7.80 | Post-conditioning with sevoflurane induces heme oxygenase-1 expression via the PI3K/Akt pathway in lipopolysaccharide-induced acute lung injury. ( Ai, Y; Wu, J; Zhang, L; Zhao, S, 2014) |
| "To explore the protective mechanisms of sevoflurane against acute lung injury (ALI) induced by one-lung ventilation (OLV) in view of cyclooxygenase-2 (COX2) and 5-lipoxygenase (5-LOX) pathways." | 7.79 | Protective mechanisms of sevoflurane against one-lung ventilation-induced acute lung injury: role of cyclooxygenase-2 and 5-lipoxygenase pathways. ( Li, J; Li, Y; Liu, R; Luo, J; Ma, Q; Sun, J; Wang, D, 2013) |
| "To investigate the effect of 3 concentrations of sevoflurane pretreatment on acute lung injury induced by endotoxin in rats." | 7.76 | Effect of different concentrations of sevoflurane pretreatment on acute lung injury induced by endotoxin in rats. ( Guo, Q; Wu, J; Ye, Z; Zhang, Z; Zhao, S, 2010) |
| " Sevoflurane combined with oxygen is widely applied in the clinic, and our previous study indicated that this regimen significantly reduced sepsis-induced inflammatory responses and that inhibition of NF-κB pathway activation may contribute to this protection effect." | 5.56 | A subanesthetic dose of sevoflurane combined with oxygen exerts bactericidal effects and prevents lung injury through the nitric oxide pathway during sepsis. ( Hou, L; Hu, Y; Luo, D; Luo, Z; Ma, H; Zhang, E; Zhao, X, 2020) |
| "Sevoflurane has a lung protective effect in ALI as it reportedly has anti‑inflammatory and apoptotic‑regulating activity." | 5.51 | Sevoflurane alleviates LPS‑induced acute lung injury via the microRNA‑27a‑3p/TLR4/MyD88/NF‑κB signaling pathway. ( Li, X; Liu, G; Shen, D; Tian, J; Wang, Y; Zhang, X, 2019) |
| "Sevoflurane was shown to exert lung protective effect during LPS-induced ALI by modulating expression level of microRNAs (miRNAs), specifically miR-155." | 5.48 | Poly r(C) binding protein 1-mediated regulation of microRNA expression underlies post-sevoflurane amelioration of acute lung injury in rats. ( Gao, C; Wang, F; Wang, J; Wang, X; Zhao, X, 2018) |
| "Sevoflurane has a stimulating effect on ENaC and Na(+) /K(+) -ATPase in vitro in LPS-injured AECII." | 5.38 | Sevoflurane reduces severity of acute lung injury possibly by impairing formation of alveolar oedema. ( Beck-Schimmer, B; Booy, C; Lachmann, RA; Leutert, AC; Schläpfer, M; Voigtsberger, S, 2012) |
| "Sevoflurane is considered as a lung-protective factor in acute lung injury (ALI), but the underlying molecular mechanism remains largely unknown." | 4.12 | Sevoflurane anesthesia ameliorates LPS-induced acute lung injury (ALI) by modulating a novel LncRNA LINC00839/miR-223/NLRP3 axis. ( Fu, Z; Wu, X; Zhang, Y; Zheng, F, 2022) |
| "Sevoflurane anesthesia is deemed as potential therapeutic drug for lipopolysaccharide (LPS)-induced acute lung injury (ALI), but the molecular mechanisms have not been fully delineated." | 4.12 | Activation of the AMPK-ULK1 pathway mediated protective autophagy by sevoflurane anesthesia restrains LPS-induced acute lung injury (ALI). ( Fu, Z; Wu, X; Zhang, Y; Zheng, F, 2022) |
| "Sevoflurane is identified as an effective candidate drug for acute lung injury (ALI) treatment, but its curing effects and detailed mechanisms have not been fully disclosed." | 4.12 | Sevoflurane reduces lipopolysaccharide-induced apoptosis and pulmonary fibrosis in the RAW264.7 cells and mice models to ameliorate acute lung injury by eliminating oxidative damages. ( Fu, Z; Wu, X; Zhang, J; Zhang, Y; Zheng, F, 2022) |
| "Sevoflurane (Sev) has protective effects in acute lung injury (ALI), but the relevant mechanisms are still not fully understood." | 4.02 | Sevoflurane inhibits ferroptosis: A new mechanism to explain its protective role against lipopolysaccharide-induced acute lung injury. ( Li, K; Liu, X; Ma, X; Mao, L; Si, J; Wang, L; Xing, Q, 2021) |
| "Evidence has shown that sevoflurane plays a protective role in acute lung injury (ALI) due to its anti-inflammatory and apoptotic-regulating activity." | 3.96 | Sevoflurane reduces inflammatory factor expression, increases viability and inhibits apoptosis of lung cells in acute lung injury by microRNA-34a-3p upregulation and STAT1 downregulation. ( Yuan, J; Zhang, Y, 2020) |
| "In animal models, both sevoflurane and propofol protect against acute lung injury (ALI), especially when administered prior to ALI onset." | 3.85 | Sevoflurane Posttreatment Attenuates Lung Injury Induced by Oleic Acid in Dogs. ( Du, G; Li, Z; Liu, J; Wang, S, 2017) |
| " This investigation explored the protective effects of propofol and whether propofol potentiates the protective effects of sevoflurane against lipopolysaccharide (LPS)-induced acute lung injury." | 3.85 | Propofol Potentiates Sevoflurane-Induced Inhibition of Nuclear Factor--κB-Mediated Inflammatory Responses and Regulation of Mitogen-Activated Protein Kinases Pathways via Toll-like Receptor 4 Signaling in Lipopolysaccharide-Induced Acute Lung Injury in Mi ( Fang, H; Liu, W; Zhu, H, 2017) |
| "Preconditioning with sevoflurane (SEV) can protect against ischemia-reperfusion injury in several organs, however, the benefits of SEV against acute lung injury (ALI), induced by intestinal ischemia-reperfusion (IIR), and the underlying mechanisms remain to be elucidated." | 3.81 | Sevoflurane ameliorates intestinal ischemia-reperfusion-induced lung injury by inhibiting the synergistic action between mast cell activation and oxidative stress. ( Chen, H; Hei, Z; Luo, C; Luo, G; Su, G; Yuan, D; Zhao, W, 2015) |
| "The aim of the present study was to explore the regulatory mechanism of heme oxygenase-1 (HO-1) expression induced by sevoflurane (Sevo) in lipopolysaccharide (LPS)‑induced acute lung injury (ALI)." | 3.80 | Post-conditioning with sevoflurane induces heme oxygenase-1 expression via the PI3K/Akt pathway in lipopolysaccharide-induced acute lung injury. ( Ai, Y; Wu, J; Zhang, L; Zhao, S, 2014) |
| "To explore the protective mechanisms of sevoflurane against acute lung injury (ALI) induced by one-lung ventilation (OLV) in view of cyclooxygenase-2 (COX2) and 5-lipoxygenase (5-LOX) pathways." | 3.79 | Protective mechanisms of sevoflurane against one-lung ventilation-induced acute lung injury: role of cyclooxygenase-2 and 5-lipoxygenase pathways. ( Li, J; Li, Y; Liu, R; Luo, J; Ma, Q; Sun, J; Wang, D, 2013) |
| "To observe the effects of sevoflurane treatment on lung inflammation in rats with lipopoIysaccharide-induced acute lung injury (ALI)." | 3.79 | Preventive effects of sevoflurane treatment on lung inflammation in rats. ( Liu, GZ; Song, SY; Tian, JM; Yang, SM; Yue, XQ; Zhou, B, 2013) |
| " We hypothesized that the volatile anesthetic sevoflurane (SEVO) attenuates lung inflammation through activation of lung epithelial GABA(A) receptors." | 3.78 | Effects of anesthetic regimes on inflammatory responses in a rat model of acute lung injury. ( Fortis, S; Haitsma, JJ; Lu, WY; Mazer, CD; Parotto, M; Slutsky, AS; Spieth, PM; Zhang, H; Zhong, N, 2012) |
| "To investigate the effect of 3 concentrations of sevoflurane pretreatment on acute lung injury induced by endotoxin in rats." | 3.76 | Effect of different concentrations of sevoflurane pretreatment on acute lung injury induced by endotoxin in rats. ( Guo, Q; Wu, J; Ye, Z; Zhang, Z; Zhao, S, 2010) |
| " Sevoflurane combined with oxygen is widely applied in the clinic, and our previous study indicated that this regimen significantly reduced sepsis-induced inflammatory responses and that inhibition of NF-κB pathway activation may contribute to this protection effect." | 1.56 | A subanesthetic dose of sevoflurane combined with oxygen exerts bactericidal effects and prevents lung injury through the nitric oxide pathway during sepsis. ( Hou, L; Hu, Y; Luo, D; Luo, Z; Ma, H; Zhang, E; Zhao, X, 2020) |
| "Sevoflurane has a lung protective effect in ALI as it reportedly has anti‑inflammatory and apoptotic‑regulating activity." | 1.51 | Sevoflurane alleviates LPS‑induced acute lung injury via the microRNA‑27a‑3p/TLR4/MyD88/NF‑κB signaling pathway. ( Li, X; Liu, G; Shen, D; Tian, J; Wang, Y; Zhang, X, 2019) |
| "Sevoflurane was shown to exert lung protective effect during LPS-induced ALI by modulating expression level of microRNAs (miRNAs), specifically miR-155." | 1.48 | Poly r(C) binding protein 1-mediated regulation of microRNA expression underlies post-sevoflurane amelioration of acute lung injury in rats. ( Gao, C; Wang, F; Wang, J; Wang, X; Zhao, X, 2018) |
| "Pretreatment with sevoflurane effectively attenuates direct severe lung injury, possibly by inhibition of neutrophil accumulation and alteration of the surfactant composition." | 1.40 | Pretreatment with sevoflurane attenuates direct lung injury. ( Fragopoulou, E; Kalimeris, K; Karamitopoulou, E; Kostopanagiotou, G; Matsota, P; Nomikos, T; Politi, AN; Zerva, A, 2014) |
| "Sevoflurane has a stimulating effect on ENaC and Na(+) /K(+) -ATPase in vitro in LPS-injured AECII." | 1.38 | Sevoflurane reduces severity of acute lung injury possibly by impairing formation of alveolar oedema. ( Beck-Schimmer, B; Booy, C; Lachmann, RA; Leutert, AC; Schläpfer, M; Voigtsberger, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 8 (32.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fu, Z | 4 |
| Wu, X | 4 |
| Zheng, F | 4 |
| Zhang, Y | 4 |
| Zhang, J | 2 |
| Yuan, J | 1 |
| Zhang, E | 1 |
| Zhao, X | 2 |
| Ma, H | 1 |
| Luo, D | 1 |
| Hu, Y | 1 |
| Hou, L | 1 |
| Luo, Z | 1 |
| Liang, Z | 1 |
| Zhou, H | 1 |
| Tang, R | 1 |
| Zhang, S | 1 |
| Chen, X | 1 |
| Pei, L | 1 |
| Liu, X | 1 |
| Wang, L | 2 |
| Xing, Q | 1 |
| Li, K | 1 |
| Si, J | 1 |
| Ma, X | 1 |
| Mao, L | 1 |
| Du, G | 1 |
| Wang, S | 1 |
| Li, Z | 1 |
| Liu, J | 1 |
| Wang, X | 1 |
| Wang, F | 1 |
| Gao, C | 1 |
| Wang, J | 1 |
| Liu, W | 1 |
| Zhu, H | 1 |
| Fang, H | 1 |
| Wang, Y | 1 |
| Zhang, X | 1 |
| Tian, J | 1 |
| Liu, G | 1 |
| Li, X | 1 |
| Shen, D | 1 |
| Liu, R | 1 |
| Luo, J | 1 |
| Li, J | 1 |
| Ma, Q | 1 |
| Sun, J | 1 |
| Li, Y | 1 |
| Wang, D | 1 |
| Kalimeris, K | 1 |
| Zerva, A | 1 |
| Matsota, P | 1 |
| Nomikos, T | 1 |
| Fragopoulou, E | 1 |
| Politi, AN | 1 |
| Karamitopoulou, E | 1 |
| Kostopanagiotou, G | 1 |
| Chelazzi, C | 1 |
| Zhao, S | 2 |
| Wu, J | 2 |
| Zhang, L | 1 |
| Ai, Y | 1 |
| Luo, C | 1 |
| Yuan, D | 1 |
| Zhao, W | 1 |
| Chen, H | 1 |
| Luo, G | 1 |
| Su, G | 1 |
| Hei, Z | 1 |
| Sun, XJ | 1 |
| Li, XQ | 1 |
| Wang, XL | 1 |
| Tan, WF | 1 |
| Wang, JK | 1 |
| Kellner, P | 1 |
| Müller, M | 1 |
| Piegeler, T | 1 |
| Eugster, P | 1 |
| Booy, C | 3 |
| Schläpfer, M | 3 |
| Beck-Schimmer, B | 3 |
| Ye, Y | 1 |
| Su, HB | 1 |
| Yang, JP | 1 |
| Steurer, M | 2 |
| Z'graggen, BR | 1 |
| Reyes, L | 1 |
| Spahn, DR | 1 |
| Guo, Q | 1 |
| Zhang, Z | 1 |
| Ye, Z | 1 |
| Leutert, AC | 1 |
| Voigtsberger, S | 1 |
| Lachmann, RA | 1 |
| Fortis, S | 1 |
| Spieth, PM | 1 |
| Lu, WY | 1 |
| Parotto, M | 1 |
| Haitsma, JJ | 1 |
| Slutsky, AS | 1 |
| Zhong, N | 1 |
| Mazer, CD | 1 |
| Zhang, H | 1 |
| Song, SY | 1 |
| Zhou, B | 1 |
| Yang, SM | 1 |
| Liu, GZ | 1 |
| Tian, JM | 1 |
| Yue, XQ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sevoflurane Sedation: A Potentially Promising Immunomodulation in Patients With Septic Shock[NCT03643367] | Phase 2 | 153 participants (Anticipated) | Interventional | 2025-01-31 | Not yet recruiting | ||
| AnaConDa-therapy in COVID-19 Patients[NCT05586126] | 42 participants (Actual) | Observational | 2020-10-01 | Terminated (stopped due to Concerns about possible association between drug and increased ICU mortality) | |||
| A Randomized Pilot Clinical Trial of the Effects in Oxygenation and Hypoxic Pulmonary Vasoconstriction of Sevoflurane in Patient's Whit ARDS Secondary to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2)[NCT04998253] | Early Phase 1 | 24 participants (Actual) | Interventional | 2020-10-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
25 other studies available for sevoflurane and Lung Injury, Acute
| Article | Year |
|---|---|
Sevoflurane anesthesia ameliorates LPS-induced acute lung injury (ALI) by modulating a novel LncRNA LINC00839/miR-223/NLRP3 axis.
Topics: Acute Lung Injury; Anesthesia; Animals; Endothelial Cells; Humans; Lipopolysaccharides; Mice; MicroR | 2022 |
Sevoflurane suppresses NLRP3 inflammasome-mediated pyroptotic cell death to attenuate lipopolysaccharide-induced acute lung injury through inducing GSK-3β phosphorylation and activation.
Topics: Acute Lung Injury; Animals; Glycogen Synthase Kinase 3 beta; Inflammasomes; Inflammation; Lipopolysa | 2022 |
Activation of the AMPK-ULK1 pathway mediated protective autophagy by sevoflurane anesthesia restrains LPS-induced acute lung injury (ALI).
Topics: Acute Lung Injury; AMP-Activated Protein Kinases; Anesthesia; Animals; Autophagy; Autophagy-Related | 2022 |
Sevoflurane reduces lipopolysaccharide-induced apoptosis and pulmonary fibrosis in the RAW264.7 cells and mice models to ameliorate acute lung injury by eliminating oxidative damages.
Topics: Acute Lung Injury; Animals; Antioxidants; Apoptosis; Kelch-Like ECH-Associated Protein 1; Lipopolysa | 2022 |
Sevoflurane reduces inflammatory factor expression, increases viability and inhibits apoptosis of lung cells in acute lung injury by microRNA-34a-3p upregulation and STAT1 downregulation.
Topics: Acute Lung Injury; Administration, Inhalation; Animals; Antagomirs; Apoptosis; Cell Survival; Down-R | 2020 |
A subanesthetic dose of sevoflurane combined with oxygen exerts bactericidal effects and prevents lung injury through the nitric oxide pathway during sepsis.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Bronchoalveolar Lavage F | 2020 |
Autologous transplantation of adipose-derived stromal cells combined with sevoflurane ameliorates acute lung injury induced by cecal ligation and puncture in rats.
Topics: Acute Lung Injury; Adipose Tissue; Animals; Bronchoalveolar Lavage Fluid; Cecum; Cell- and Tissue-Ba | 2020 |
Sevoflurane inhibits ferroptosis: A new mechanism to explain its protective role against lipopolysaccharide-induced acute lung injury.
Topics: Acute Lung Injury; Animals; Blotting, Western; Cell Line; Ferroptosis; Humans; Lipopolysaccharides; | 2021 |
Sevoflurane Posttreatment Attenuates Lung Injury Induced by Oleic Acid in Dogs.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Animals; Arterial Pressure; Cytoprotection; Disease Mode | 2017 |
Poly r(C) binding protein 1-mediated regulation of microRNA expression underlies post-sevoflurane amelioration of acute lung injury in rats.
Topics: Acute Lung Injury; Animals; Carrier Proteins; Gene Expression Regulation; Heterogeneous-Nuclear Ribo | 2018 |
Propofol Potentiates Sevoflurane-Induced Inhibition of Nuclear Factor--κB-Mediated Inflammatory Responses and Regulation of Mitogen-Activated Protein Kinases Pathways via Toll-like Receptor 4 Signaling in Lipopolysaccharide-Induced Acute Lung Injury in Mi
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Drug Synergism; Lipop | 2017 |
Sevoflurane alleviates LPS‑induced acute lung injury via the microRNA‑27a‑3p/TLR4/MyD88/NF‑κB signaling pathway.
Topics: Acute Lung Injury; Animals; Anti-Inflammatory Agents; Apoptosis; Lipopolysaccharides; Male; Mice, In | 2019 |
Protective mechanisms of sevoflurane against one-lung ventilation-induced acute lung injury: role of cyclooxygenase-2 and 5-lipoxygenase pathways.
Topics: Acute Lung Injury; Animals; Arachidonate 5-Lipoxygenase; Cyclooxygenase 2; Lung; Methyl Ethers; One- | 2013 |
Pretreatment with sevoflurane attenuates direct lung injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Animals; Bronchoalveolar Lavage Fluid; Lipopolysaccharid | 2014 |
Sevoflurane: going beyond anesthesia, cardiac conditioning and organ toxicity.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Animals; Male; Methyl Ethers; Sevoflurane | 2014 |
Post-conditioning with sevoflurane induces heme oxygenase-1 expression via the PI3K/Akt pathway in lipopolysaccharide-induced acute lung injury.
Topics: Acute Lung Injury; Animals; Disease Models, Animal; Gene Expression Regulation; Heme Oxygenase-1; Li | 2014 |
Sevoflurane ameliorates intestinal ischemia-reperfusion-induced lung injury by inhibiting the synergistic action between mast cell activation and oxidative stress.
Topics: Acetophenones; Acute Lung Injury; Anesthetics, Inhalation; Animals; Antioxidants; Cell Degranulation | 2015 |
Sevoflurane inhibits nuclear factor-κB activation in lipopolysaccharide-induced acute inflammatory lung injury via toll-like receptor 4 signaling.
Topics: Acetylcholine; Acute Lung Injury; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bronchoalveolar | 2015 |
Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Anti-Inflammatory Age | 2017 |
Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Anti-Inflammatory Age | 2017 |
Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Anti-Inflammatory Age | 2017 |
Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Anti-Inflammatory Age | 2017 |
Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Anti-Inflammatory Age | 2017 |
Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Anti-Inflammatory Age | 2017 |
Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Anti-Inflammatory Age | 2017 |
Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Anti-Inflammatory Age | 2017 |
Sevoflurane Abolishes Oxygenation Impairment in a Long-Term Rat Model of Acute Lung Injury.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Anesthetics, Intravenous; Animals; Anti-Inflammatory Age | 2017 |
The anesthetic agent sevoflurane attenuates pulmonary acute lung injury by modulating apoptotic pathways.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Animals; Apoptosis; Immunohistochemistry; In Situ Nick-E | 2017 |
The volatile anaesthetic sevoflurane attenuates lipopolysaccharide-induced injury in alveolar macrophages.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Animals; Cell Line; Chemokine CCL2; Chemokine CXCL1; Che | 2009 |
Effect of different concentrations of sevoflurane pretreatment on acute lung injury induced by endotoxin in rats.
Topics: Acute Lung Injury; Anesthetics, Inhalation; Animals; Dose-Response Relationship, Drug; Intercellular | 2010 |
Sevoflurane reduces severity of acute lung injury possibly by impairing formation of alveolar oedema.
Topics: Acute Lung Injury; Anesthetics; Animals; Biological Transport, Active; Cell Line; Cell Survival; Lip | 2012 |
Effects of anesthetic regimes on inflammatory responses in a rat model of acute lung injury.
Topics: Acute Lung Injury; Analysis of Variance; Anesthesia; Anesthetics, Dissociative; Anesthetics, General | 2012 |
Preventive effects of sevoflurane treatment on lung inflammation in rats.
Topics: Acute Lung Injury; Administration, Inhalation; Animals; Gene Expression; Intercellular Adhesion Mole | 2013 |